{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:47:27Z","timestamp":1792194447307,"version":"4.4.0"},"reference-count":117,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprclinrheum.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.berh.2014.03.005","type":"journal-article","created":{"date-parts":[[2014,6,26]],"date-time":"2014-06-26T09:47:37Z","timestamp":1403776057000},"page":"293-313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Therapeutic advancements in juvenile idiopathic arthritis"],"prefix":"10.1016","volume":"28","author":[{"given":"Elizabeth A.","family":"Kessler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara L.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2014.03.005_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.23177","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I","volume":"58","author":"Helmick","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib2","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib3","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/715352","article-title":"Disease activity measures in paediatric rheumatic diseases","volume":"2013","author":"Luca","year":"2013","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib5","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/art.24516","article-title":"Development and validation of a composite disease activity score for juvenile idiopathic arthritis","volume":"61","author":"Consolaro","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib6","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/acr.20205","volume":"62","author":"Ringold","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2014.03.005_bib7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/clpt.2011.293","article-title":"Optimization of pediatric rheumatology therapeutics","volume":"91","author":"Becker","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.berh.2014.03.005_bib8","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.berh.2014.03.005_bib9","doi-asserted-by":"crossref","first-page":"e1384","DOI":"10.1542\/peds.2013-0755","article-title":"Using registries to identify adverse events in rheumatic diseases","volume":"132","author":"Lionetti","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.berh.2014.03.005_bib10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/ar4213","article-title":"What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?","volume":"15","author":"Swart","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2014.03.005_bib11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features","volume":"63","author":"Beukelman","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2014.03.005_bib12","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/acr.22087","volume":"65","author":"Ringold","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.berh.2014.03.005_bib13","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1172\/JCI116884","article-title":"The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in\u00a0vivo model of inflammation","volume":"92","author":"Cronstein","year":"1993","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.berh.2014.03.005_bib14","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1056\/NEJM199204163261602","article-title":"Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and the Cooperative Children's Study Group","volume":"326","author":"Giannini","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2014.03.005_bib15","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3899\/jrheum.090826","article-title":"Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: comparison of 2 initial dosing regimens","volume":"37","author":"Becker","year":"2010","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib16","first-page":"1604","article-title":"Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis","volume":"19","author":"Wallace","year":"1992","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib17","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/art.20288","article-title":"A\u00a0randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate","volume":"50","author":"Ruperto","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib18","first-page":"179","article-title":"The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate","volume":"31","author":"Alsufyani","year":"2004","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib19","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/acr.21697","article-title":"Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis. An observational study with patients of the German Methotrexate Registry","volume":"64","author":"Klein","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.berh.2014.03.005_bib20","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2010.375","article-title":"Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial","volume":"303","author":"Foell","year":"2010","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.berh.2014.03.005_bib21","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/art.30080","article-title":"The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response","volume":"63","author":"Becker","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib22","doi-asserted-by":"crossref","unstructured":"Bulatovic Calasan M, den Boer E, de Rotte M.C. et al., Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients, Ann Rheum Dis Published Online First [2013 Nov 28]. http:\/\/dx.doi.org\/10.1136\/annrheumdis-2013-203723.","DOI":"10.1136\/annrheumdis-2013-203723"},{"key":"10.1016\/j.berh.2014.03.005_bib23","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FPC.0b013e3283500202","article-title":"Red blood cell folate concentrations and polyglutamate distribution in juvenile arthritis: predictors of folate variability","volume":"22","author":"Becker","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.berh.2014.03.005_bib24","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1136\/ard.2010.146191","article-title":"Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis","volume":"70","author":"Hinks","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.03.005_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-0381-6-1","article-title":"Risk score modeling of multiple gene to gene interactions using aggregated-multifactor dimensionality reduction","volume":"6","author":"Dai","year":"2013","journal-title":"BioData Min"},{"key":"10.1016\/j.berh.2014.03.005_bib26","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/FPC.0b013e32833f2cd0","article-title":"Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype","volume":"20","author":"Moncrieffe","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.berh.2014.03.005_bib27","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.3899\/jrheum.111593","article-title":"ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis","volume":"39","author":"de Rotte","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib28","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1136\/annrheumdis-2011-200942","article-title":"Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis","volume":"71","author":"Bulatovic","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.03.005_bib29","first-page":"480","article-title":"Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study","volume":"25","author":"van der Meer","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3899\/jrheum.120753","article-title":"Methotrexate and injectable tumor necrosis factor-alpha inhibitor adherence and persistence in children with rheumatic diseases","volume":"40","author":"Ringold","year":"2013","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib31","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/art.1780401218","article-title":"The long-term effect of methotrexate therapy on the liver in patients with juvenile rheumatoid arthritis","volume":"40","author":"Hashkes","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib32","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/art.34343","article-title":"Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis","volume":"64","author":"Wallace","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib33","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F","article-title":"Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis","volume":"43","author":"Woo","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib34","first-page":"297","article-title":"Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype","volume":"9","author":"Halle","year":"1991","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib35","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/acr.21625","article-title":"Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis","volume":"64","author":"DeWitt","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2014.03.005_bib36","first-page":"865","article-title":"Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"28","author":"Ravelli","year":"2001","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib37","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s100670050027","article-title":"Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study","volume":"19","author":"Biasi","year":"2000","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib38","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa041810","article-title":"Leflunomide or methotrexate for juvenile rheumatoid arthritis","volume":"352","author":"Silverman","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2014.03.005_bib39","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/art.20861","article-title":"Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis","volume":"52","author":"Silverman","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib40","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.3899\/jrheum.090874","article-title":"Effectiveness of leflunomide in patients with juvenile idiopathic arthritis in clinical practice","volume":"37","author":"Foeldvari","year":"2010","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib41","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.4049\/jimmunol.156.5.1937","article-title":"The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites","volume":"156","author":"Gadangi","year":"1996","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.berh.2014.03.005_bib42","first-page":"722","article-title":"Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials","volume":"33","author":"Chen","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib43","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/1529-0131(199805)41:5<808::AID-ART6>3.0.CO;2-T","article-title":"Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group","volume":"41","author":"van Rossum","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib44","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1136\/ard.2006.064717","article-title":"Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment","volume":"66","author":"van Rossum","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.03.005_bib45","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1136\/ard.61.10.941","article-title":"A\u00a026 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies","volume":"61","author":"Burgos-Vargas","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.03.005_bib46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/ard.2006.057133","article-title":"Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study","volume":"66","author":"Capell","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.03.005_bib47","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/ard.2010.143347","article-title":"Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial","volume":"70","author":"Tynjala","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.03.005_bib48","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2014.03.005_bib49","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2014.03.005_bib50","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A\u00a0randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib51","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/art.24777","article-title":"Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis","volume":"60","author":"Giannini","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib52","first-page":"867","article-title":"Good results from combining etanercept to prevailing DMARD therapy in refractory juvenile idiopathic arthritis","volume":"20","author":"Haapasaari","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib53","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/ard.61.2.171","article-title":"Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period","volume":"61","author":"Kietz","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.03.005_bib54","first-page":"2286","article-title":"Etanercept does not essentially increase the total costs of the treatment of refractory juvenile idiopathic arthritis","volume":"31","author":"Haapasaari","year":"2004","journal-title":"J\u00a0Rheumatol"},{"issue":"Suppl. 1","key":"10.1016\/j.berh.2014.03.005_bib55","first-page":"S36","volume":"89","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl. 1","key":"10.1016\/j.berh.2014.03.005_bib56","first-page":"S36","article-title":"Association of infliximab clearance and resting energy expenditure in children","volume":"89","author":"Goldman","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.berh.2014.03.005_bib57","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ophtha.2006.01.005","article-title":"Favorable response to high-dose infliximab for refractory childhood uveitis","volume":"113","author":"Kahn","year":"2006","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.berh.2014.03.005_bib58","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ibd.20177","article-title":"Infliximab dose intensification in Crohn's disease","volume":"13","author":"Regueiro","year":"2007","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"10.1016\/j.berh.2014.03.005_bib59","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.3899\/jrheum.130133","article-title":"High doses of infliximab in the management of juvenile idiopathic arthritis","volume":"40","author":"Tambralli","year":"2013","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib60","series-title":"ClinicalTrials.gov [Internet]","article-title":"A\u00a0study of the safety and efficacy of CNTO 148 (golimumab) in children with juvenile idiopathic arthritis (JIA) and multiple joint involvement who have poor response to methotrexate (GO KIDS)","author":"Janssen Research & Development, LLC","year":"2000"},{"key":"10.1016\/j.berh.2014.03.005_bib61","series-title":"ClinicalTrials.gov [Internet]","article-title":"Pediatric arthritis study of certolizumab pegol (PASCAL)","author":"UCB BIOSCIENCES GmbH","year":"2000"},{"issue":"2","key":"10.1016\/j.berh.2014.03.005_bib62","first-page":"CD007649","article-title":"Certolizumab pegol (CDP870) for rheumatoid arthritis in adults","author":"Ruiz Garcia","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.berh.2014.03.005_bib63","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3899\/jrheum.091466","article-title":"Golimumab for rheumatoid arthritis: a systematic review","volume":"37","author":"Singh","year":"2010","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib64","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrrheum.2010.142","article-title":"The safety profile of biologic therapies for juvenile idiopathic arthritis","volume":"6","author":"Hashkes","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib65","first-page":"825","article-title":"Septic abscess in a child with juvenile idiopathic arthritis receiving anti-tumor necrosis factor-alpha","volume":"33","author":"Fitch","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib66","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10067-010-1410-x","article-title":"Serious musculoskeletal infections in children receiving anti-tumor necrosis factor-alpha therapy: a case series","volume":"29","author":"Morishita","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib67","article-title":"Childhood arthritis and rheumatology research alliance consensus treatment plans for new onset polyarticular juvenile idiopathic arthritis","author":"Ringold","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2014.03.005_bib68","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/art.34458","article-title":"Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib69","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/ard.62.3.245","article-title":"Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study","volume":"62","author":"Lahdenne","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.03.005_bib70","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/ard.2007.087130","article-title":"Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis","volume":"68","author":"Tynjala","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.03.005_bib71","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","article-title":"Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis","volume":"50","author":"Pascual-Salcedo","year":"2011","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.berh.2014.03.005_bib72","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis","volume":"66","author":"Bartelds","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.03.005_bib73","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/art.22214","article-title":"Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab","volume":"54","author":"Bendtzen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib74","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2014.03.005_bib75","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/art.27511","article-title":"Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration","volume":"62","author":"Diak","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib76","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions : a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.berh.2014.03.005_bib77","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.34348","article-title":"Rates of malignancy associated with juvenile idiopathic arthritis and its treatment","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib78","article-title":"Juvenile idiopathic arthritis and malignancy","author":"Ruperto","year":"2013","journal-title":"Rheumatology (Oxford, England)"},{"issue":"1","key":"10.1016\/j.berh.2014.03.005_bib79","doi-asserted-by":"crossref","first-page":"e30275","DOI":"10.1371\/journal.pone.0030275","article-title":"Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis","volume":"7","author":"Aaltonen","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.berh.2014.03.005_bib80","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/ard.2007.087593","article-title":"Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry","volume":"68","author":"Horneff","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.03.005_bib81","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s13105-010-0022-x","article-title":"Etanercept reduces matrix metalloproteinase-9 level in children with polyarticular juvenile idiopathic arthritis and TNF-alpha-308GG genotype","volume":"66","author":"Basic","year":"2010","journal-title":"J\u00a0Physiol Biochem"},{"key":"10.1016\/j.berh.2014.03.005_bib82","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00296-006-0208-2","article-title":"Tumour necrosis factor alpha promoter polymorphisms and etanercept therapy in juvenile idiopathic arthritis","volume":"27","author":"Schmeling","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2014.03.005_bib83","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1136\/ard.2006.067454","article-title":"IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors","volume":"66","author":"Cimaz","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.03.005_bib84","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/art.30130","article-title":"Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci","volume":"63","author":"Plant","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib85","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/ibd.21174","article-title":"Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease","volume":"16","author":"Dubinsky","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.berh.2014.03.005_bib86","doi-asserted-by":"crossref","first-page":"R230","DOI":"10.1186\/ar4072","article-title":"Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement","volume":"14","author":"Horneff","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2014.03.005_bib87","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.3899\/jrheum.110145","article-title":"Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis \u2013 data from the Dutch arthritis and biologicals in children register, 1999-2010","volume":"38","author":"Otten","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib88","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2012-eular.2783","article-title":"Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study","author":"Horneff","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.03.005_bib89","article-title":"Long-term outcome of anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondyloarthritis","author":"Hugle","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib90","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23471","article-title":"Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2014.03.005_bib91","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1186\/ar2794","article-title":"Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years","volume":"11","author":"van der Heijde","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2014.03.005_bib92","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2014.03.005_bib93","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/art.27431","article-title":"Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis","volume":"62","author":"Ruperto","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2014.03.005_bib94","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.berh.2014.03.005_bib95","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/art.22070","article-title":"Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study","volume":"54","author":"Weinblatt","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib96","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10067-008-0995-9","article-title":"Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study","volume":"28","author":"Ilowite","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib97","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A\u00a0multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.03.005_bib98","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.30128","article-title":"Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series","volume":"63","author":"Nigrovic","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib99","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first line use of recombinant IL-1RA treatment in steroid naive systemic juvenile idiopathic arthritis: results of a prospective cohort study","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib100","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib101","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1358\/dot.2009.45.6.1378935","article-title":"Rilonacept in the treatment of chronic inflammatory disorders","volume":"45","author":"McDermott","year":"2009","journal-title":"Drugs Today"},{"key":"10.1016\/j.berh.2014.03.005_bib102","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/art.38042","article-title":"Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis","volume":"65","author":"Lovell","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib103","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2014.03.005_bib104","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/annrheumdis-2012-202310","article-title":"Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan","volume":"72","author":"Yokota","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.03.005_bib105","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","article-title":"Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis","volume":"367","author":"De Benedetti","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl. 10","key":"10.1016\/j.berh.2014.03.005_bib106","first-page":"1597","article-title":"Efficacy and safety of tocilizumab in patients with polyarticular juvenile idiopathic arthritis: data from a phase 3 trial","volume":"64","author":"Brunner","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib107","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10067-011-1720-7","article-title":"Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis","volume":"30","author":"Alexeeva","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib108","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/art.30194","article-title":"Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial","volume":"63","author":"Greenwald","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib109","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/art.34329","article-title":"The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4+ T cells","volume":"64","author":"Maeshima","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib110","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s10067-013-2329-9","article-title":"The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis","volume":"32","author":"Kawalec","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib111","series-title":"ClinicalTrials.gov [Internet]","article-title":"An open-label multiple dose study to evaluate the pharmacokinetics, safety and tolerability of CP-690,550 in pediatric patients from 2 to less than 18 years of age with juvenile idiopathic arthritis (JIA)","author":"Pfizer","year":"2000"},{"key":"10.1016\/j.berh.2014.03.005_bib112","series-title":"ClinicalTrials.gov [Internet]","article-title":"A\u00a0long-term, open-label follow-up study of CP-690,550 for treatment of juvenile idiopathic arthritis (JIA)","author":"Pfizer","year":"2000"},{"key":"10.1016\/j.berh.2014.03.005_bib113","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/acr.20497","article-title":"American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis","volume":"63","author":"Wallace","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2014.03.005_bib114","first-page":"2290","article-title":"Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis","volume":"31","author":"Wallace","year":"2004","journal-title":"J\u00a0Rheumatol"},{"issue":"4 Suppl. 23","key":"10.1016\/j.berh.2014.03.005_bib115","first-page":"S163","article-title":"The British version of the childhood health assessment questionnaire (CHAQ) and the child health questionnaire (CHQ)","volume":"19","author":"Nugent","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2014.03.005_bib116","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/art.10095","article-title":"The PedsQL in pediatric rheumatology: reliability, validity, and responsiveness of the Pediatric Quality of Life Inventory Generic Core Scales and Rheumatology Module","volume":"46","author":"Varni","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.03.005_bib117","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1023\/A:1008810004694","article-title":"Canadian-French, German and UK versions of the Child Health Questionnaire: methodology and preliminary item scaling results","volume":"7","author":"Landgraf","year":"1998","journal-title":"Qual Life Res"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694214000229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694214000229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T01:41:08Z","timestamp":1716860468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694214000229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":117,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S1521694214000229"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2014.03.005","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic advancements in juvenile idiopathic arthritis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2014.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}